

LUC
0
10
20
30
40
0
0.1
0.2
0.5
1
2
5
Butyrate (mM)
LUC
0
10
20
30
0
0.1
0.2
0.5
1
2
5
Valproate (mM)
LUC
0
10
20
30
0
0.01
0.1
0.2
0.5
1
2
4
5' - Azad (uM)
LUC
0
10
20
30
0
0.1
0.2
0.5
1
2
5
Valproate (mM)

FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C



RFU
30000
25000
20000
15000
10000
5000
0
0
100
300
500
1000
Azad(nM)

FIG. 3




FIG. 4

day0	1	2	3	4	5	6	7	8	9	10	11	12
A	18011	18375	19733	19990	20480	19980	20531	20596	19786	19784	19272	16272
B	18423	19526	20272	19941	20865	20698	21314	20759	21156	19806	19498	16368
C	16224	17039	18445	16899	16964	18170	17125	17096	16675	16206	15971	16811
D	17555	18058	18318	20145	19870	19919	19529	21625	19545	20014	18146	16455
E	20758	20136	19951	19839	20929	20253	19793	20059	19721	16907	16272	16643
F	19332	19023	20613	20016	19008	19743	18969	19382	17443	18730	17878	16169
G	16232	15988	15959	16338	16682	17031	17248	17954	18050	20037	19397	16297
H	16711	17728	16065	16786	16298	18953	19295	19460	20072	19185	18560	15837
3												

BX-1

RPMI

+anti-IgG

FIG. 4A



day3
1 2 3 4 5 6 7 8 9 10 11 12
A 28206 25054 40322 27800 30039 23158 29578 29313 30764 15790
B 28899 29276 34041 34503 28346 30093 33855 30640 26455 35615 16356
C 29453 23635 36968 24244 28804 26418 23579 23313 20921 20206 21088 16545
D 25854 25604 26258 25818 20248 26940 26342 29047 27235 34097 25038 16472
E 56465 26496 27788 26429 28103 30624 27840 28430 25572 21853 20670 16113
F 53591 28886 32731 27978 29681 28896 27183 28810 23983 30424 16058
G 36820 22421 21136 22620 23215 23330 24427 36006 27262 31690 27473 15724
H 46840 23551 28892 30887 23590 25038 26919 28925 30030 28702 15718
3
Doxorubicin
day17
1 2 3 4 5 6 7 8 9 10 11 12
A 24748 18470 22917 29402 29988 15010 18326 7058 25386 17975 23082 5069
B 21980 20655 28523 29514 19339 20420 20740 16821 18195 16169 23830 5215
C 22496 18290 33159 16745 23229 21244 23257 21433 22182 22235 22708 5306
D 21576 19676 19190 16909 20204 19787 20972 23296 20569 5320
E 16591 16073 18721 15424 20062 20602 20122 17275 21432 22609 5176
F 16403 19815 20229 21643 21895 20467 22109 40151 32366 5100
G 17632 20734 20291 21025 20609 22434 21019 26082 22597 23390 5152
H 18059 18172 24413 26990 22705 20611 21584 23046 16745 22222 21182 4541
1

FIG. 4B



GFP
Most glucocorticoid drugs
Anti-IgG,
PMA
Some glucocorticoid drugs
Doxorubicin
Gemcitabin
Luciferase
Methotrexate,
cis-platinum,
5-FU,
Taxol

FIG. 5





FIG. 6A
FIG. 6B

FIG. 6


nc
25.0
20.0
15.0
10.0
5.0
0.0
0
0.1
1
5
10
50
100
300
500
1000
tranilast(uM)
O
N
H
O
O
H
O
O
O
Tranilast

FIG. 6A






Leflunomide

Tranilast and Lefunomide can induce BZLF1 promoter in AGS up to 15 fold

FIG. 6B



Ara-c

FIG. 7A



fold induction
2.5
2
1.5
1
0.5
0
0
0.1
0.2
0.5
1
2
5
10
20
50
100
200
Ara-c (uM)

FIG. 7B




FIG. 7C



FIG. 8A




FIG. 8B





FIG. 8C







FIG. 8D



Indoprofen

FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B





FIG. 10C



Mebendazol

FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E

FIG. 12A





FIG. 12B






FIG. 12C




FIG. 12D




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D





FIG. 14A

FIG. 14B




72 hr

96 hr


FIG. 15A

FIG. 15B



3 hr


FIG. 16A



TK143b


24 hr

FIG. 16B



3 hr

FIG. 16C



V143b (+ bortezomib)

24 hr

FIG. 16D



Tumor
Liver
Kidney
Spleen
Muscle
%ID/gram
0
2
4
6
2
14
24
48
72
96
Hours

FIG. 17




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19A




FIG. 19B




FIG. 19C

FIG. 20B





FIG. 20A





Day 0
Day 5
Day 10
Day 15
no treatment
GCV + [131I]FIAU
Velcade + [131I]FIAU

FIG. 21



1400
1200
1000
800
600
400
200
0
Tumor volume (mm3)
Day 0 Day 2 Day 5 Day 8Day 12Day 15
Days after treatment
no treatment
[131I]FIAU + GCV
[131I]FIAU + bortezomib

FIG. 22



Bystander effect
TK expressing cell
[131I]FIAU

FIG. 23




FIG. 24



Cell Dose
<AD> = 4.36 Gy
Cells
Dose (Gy)
131 Dose Distribution vs. Cell Position
Dose (Gy)
Radius (mm)
Cell Dose
<AD> = 4.35 Gy
Cells
Dose (Gy)
131 Dose Distribution vs. Cell Position
Dose (Gy)
Radius (mm)
Cell Dose
<AD> = 4.34 Gy
Cells
Dose (Gy)
131 Dose Distribution vs. Cell Position
Dose (Gy)
Radius (mm)

FIG. 25




FIG. 26




FIG. 26A




FIG. 26B




FIG. 26C